Metabolic ALK MAPK Immune_Reactive Phases Title Class Drugs Comments
NCT02780804 YES NO NO YES 1 Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors Targeted Entinostat
NCT02909777 YES NO NO NO 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma Targeted CUDC-907 Dual PI3K, HDAC Inhibitor Neuroblastoma tumors must have MYCN or MYC amplification/expression.
NCT02030964 YES NO NO NO 1 N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan Targeted DFMO, Celecoxib, Cyclophosphamide, Topotecan
NCT02095132 YES NO NO NO 1/2 WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Targeted Irinotecan Hydrochloride, WEE1 Inhibitor AZD1775
NCT02390843 YES NO NO NO 1 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Targeted;Cytotoxic Simvastatin, Cyclophosphamide, Topotecan, Myeloid growth factor
NCT02644460 YES NO NO NO 1 Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors Targeted Abemaciclib
NCT02323880 YES NO NO NO 1 Study of Selinexor in Pediatric Solid Tumors Targeted Selinexor
NCT01711554 NANT
2011-04
NO NO NO YES 1 Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma ImmuneModulation;Antibody-ADCC Isotretinoin, Lenalidomide
NCT02304458 NO NO NO YES 1/2 Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Antibody-Immunecheckpoint
NCT02793466 NO NO NO YES 1 Durvalumab in Pediatric and Adolescent Patients Antibody-Immunecheckpoint Durvalumab; MEDI4736 PDL1 Positive Tumor Required
NCT00911560 NO NO NO YES 1/2 Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma Vaccine
NCT01606878 NO YES NO NO 1 Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Targeted;Cytotoxic crizotinib, cyclophosphamide, topotecan hydrochloride, vincristine sulfate, dexrazoxane hydrochloride, doxorubicin hydrochloride
NCT01742286 NO YES NO NO 1 Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) Targeted LDK378
NCT02650401 NO YES NO NO 1 Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors Targeted Entrectinib RXDX-101 = a small molecule inhibitor of ALK and Ros1 and TRK receptors
NCT02298348 NANT
2013-02
NO NO YES NO 1 Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma Targeted;Cytotoxic Sorafenib, Cyclophosphamide, Topotecan
NCT02780128 YES YES YES NO 1 Next Generation Personalized Neuroblastoma Therapy Targeted Ceritinib, Trametinib, HDM201, Ribociclib Tumor biopsy or separate sequencing assay may be required prior to enrollment.
NO NO NO NO
No Matches: NO NO NO NO
NO NO NO NO
NCT01163383 NO NO NO NO 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma MIBG 131 I-Metaiodobenzylguanidine (131 I-MIBG), 131 I-MIBG
NCT01370330 NO NO NO NO 131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol MIBG Metaiodobenzylguanidine (MIBG)
NCT01838187 NO NO NO NO Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma MIBG
NCT02573896 NANT
2013-01
NO NO NO NO 1 Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells Antibody-ADCC; Adoptive-NK Ch14.18, Lenalidomide
NCT02867592 NO NO NO NO 2 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Targeted Cabozantinib S-malate
NCT02932280 NO NO NO NO 1/2 Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Targeted Neratinib HER2 and EGFR Inhibitor
NCT00089245 NO NO NO NO 1 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer Antibody-Radioconjugate 8H9-I-131 intracranial Ab
NCT00445965 NO NO NO NO 2 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Antibody-Radioconjugate
NCT00877110 NO NO NO NO 1 Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma Antibody-ADCC cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
NCT01099644 NO NO NO NO 1 Intraperitoneal Radioimmunotherapy With 131I-8H9 for Patients With Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum Antibody-Radioconjugate
NCT01419834 NO NO NO NO 1 Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors Antibody-ADCC
NCT01757626 NO NO NO NO 1/2 Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma Antibody-ADCC
NCT01767194 COG
ANBL1221
NO NO NO NO 2 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma Targeted; Cytotoxic; Antibody-ADCC Irinotecan Hydrochloride, Temozolomide, Temsirolimus
NCT01962103 NO NO NO NO 1/2 To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors Cytotoxic nab-paclitaxel
NCT02311621 NO NO NO NO 1 Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01 Adoptive-CART
NCT02650648 NO NO NO NO 1 Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma Antibody-ADCC; Adoptive-NK cyclophosphamide, rIL-2